Vanda Pharmaceuticals | VNDA - Efectivo Y Equivalentes





Efectivo Y Equivalentes Cambio Fecha
Acadia Pharmaceuticals USD 956.47M 105.02M 2026-06
Agios Pharmaceuticals USD 99.65M 13.95M 2026-06
Akebia Therapeutics USD 155.55M 7.1M 2026-06
Alnylam Pharmaceuticals USD 1.71B 2.46M 2026-06
Anika Therapeutics USD 38.41M 2.61M 2026-06
Arrowhead Research USD 19.68M 127.85M 2026-06
AstraZeneca USD 4.89B 2.67B 2026-06
Bristol-Myers Squibb USD 8.72B 852M 2026-06
Eli Lilly USD 8.95B 3.67B 2026-06
Enanta Pharmaceuticals USD 37.44M 5.14M 2025-12
Halozyme Therapeutics USD 163.14M 146.61M 2026-06
Heron Therapeutics USD 20.72M 5.4M 2026-06
Insmed USD 544.76M 37.42M 2026-06
J&J USD 20.42B 1.27B 2026-06
Lexicon Pharmaceuticals USD 38.09M 3.76M 2026-03
Ligand Pharmaceuticals USD 1.01B 891.62M 2026-06
Merck USD 6.85B 1.52B 2026-06
Minerva Neurosciences USD 82.3M 70.02M 2025-12
Moderna USD 1.72B 185M 2026-06
Novartis USD 6.88B 2.68B 2026-03
Pfizer USD 976M 727M 2026-06
PTC Therapeutics USD 1.05B 215.9M 2026-06
Puma Biotechnology USD 53.52M 1.14M 2025-09
Sangamo BioSciences USD 38.34M 13.16M 2025-06
Sanofi EUR 6.35B 806M 2026-06
Takeda JPY 460.98B 134.07B 2026-06
Teva Pharmaceutical Industries USD 3.74B 185M 2026-03
Ultragenyx Pharmaceutical USD 125M 50M 2026-06
Vanda Pharmaceuticals USD 84.85M 14.83M 2025-12
Veracyte USD 299.52M 36.38M 2026-06